Covered recipient · General Payments record
SARAH K TASIAN
Allopathic & Osteopathic Physicians Pediatrics Pediatric Hematology-Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$19,866.78
23 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $14,275.00 | 3 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,348.00 | 1 |
| Travel and Lodging | $1,702.42 | 10 |
| Food and Beverage | $541.36 | 9 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $12,313.42 | 17 |
| Syndax Pharmaceuticals, Inc. | $4,054.72 | 3 |
| JAZZ PHARMACEUTICALS INC. | $3,498.64 | 3 |
Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
SARAH K TASIAN
NPI 1013027077 · CMS profile ID 1132369
Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Hematology-Oncology
PHILADELPHIA, PA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1013027077?year=2025&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- SARAH K TASIAN, NPI 1013027077, CMS profile ID 1132369. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1013027077?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). SARAH K TASIAN, NPI 1013027077, CMS profile ID 1132369. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1013027077?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- SARAH K TASIAN, NPI 1013027077, CMS profile ID 1132369, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1013027077?year=2025&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
23 matching records · $19,866.78 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–23 of 23.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| JAZZ PHARMACEUTICALS INC. | $3,348.00 | 12/17/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234299390 | CMS |
| JAZZ PHARMACEUTICALS INC. | $125.00 | 12/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234306220 | CMS |
| Syndax Pharmaceuticals, Inc. | $135.81 | 09/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238996436 | CMS |
| Syndax Pharmaceuticals, Inc. | $93.91 | 09/16/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238996438 | CMS |
| Syndax Pharmaceuticals, Inc. | $3,825.00 | 09/16/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238996440 | CMS |
| JAZZ PHARMACEUTICALS INC. | $25.64 | 05/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234328214 | CMS |
| Amgen Inc. | $66.48 | 04/02/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226917978 | CMS |
| Amgen Inc. | $8,196.00 | 04/02/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226918964 | CMS |
| Amgen Inc. | $77.46 | 04/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228304931 | CMS |
| Amgen Inc. | $2,254.00 | 03/28/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226923709 | CMS |
| Amgen Inc. | $50.45 | 02/09/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226906501 | CMS |
| Amgen Inc. | $149.77 | 02/08/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226908126 | CMS |
| Amgen Inc. | $10.44 | 02/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1227045630 | CMS |
| Amgen Inc. | $52.19 | 02/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228304927 | CMS |
| Amgen Inc. | $149.77 | 02/07/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226911671 | CMS |
| Amgen Inc. | $20.95 | 02/07/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226915491 | CMS |
| Amgen Inc. | $10.44 | 02/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1227045628 | CMS |
| Amgen Inc. | $52.19 | 02/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228304929 | CMS |
| Amgen Inc. | $836.56 | 02/06/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226906479 | CMS |
| Amgen Inc. | $149.77 | 02/06/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226908130 | CMS |
| Amgen Inc. | $140.92 | 02/06/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226915489 | CMS |
| Amgen Inc. | $43.84 | 02/06/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226915495 | CMS |
| Amgen Inc. | $52.19 | 02/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228304933 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2022, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $376,661.72 | 26 |
| PY2024 | Principal investigator | $492,636.09 | 23 |
| PY2023 | Principal investigator | $24,589.12 | 11 |
| PY2022 | Principal investigator | $39,173.75 | 6 |
| PY2021 | Principal investigator | $433.67 | 12 |
| PY2020 | Principal investigator | $178.59 | 4 |
| PY2019 | Recipient | $93.48 | 2 |
| PY2019 | Principal investigator | $326.23 | 7 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
26 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Syndax Pharmaceuticals, Inc. | $16,240.50 | 12/09/2025 | Covered Recipient Teaching Hospital THE CHILDRENS HOSPITAL OF PHILADELP | EXPANDED ACCESS PROGRAM FORSNDX-5613IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LEUKEMIAS WITH GENETIC ALTERATIONS ASSOCIATED WITH HOXA OVEREXPRESSION | No dispute reported | 06/30/2026 | 1249049738 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,675.00 | 12/08/2025 | Covered Recipient Teaching Hospital The Childrens Hospital Of Philadelp | An Open-label, First-in-human, Dose-escalation Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR-MDS) | No dispute reported | 06/30/2026 | 1226129755 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $70.00 | 12/01/2025 | Covered Recipient Teaching Hospital The Childrens Hospital Of Philadelp | A Multi-center, Open-label Study to Determine the Dose and Safety of Oral Asciminib in Pediatric Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP), Previously Treated With One or More Tyrosine Kinase Inh | No dispute reported | 06/30/2026 | 1190297481 |
| Principal investigator 1 | Syndax Pharmaceuticals, Inc. | $1,666.00 | 11/05/2025 | Covered Recipient Teaching Hospital THE CHILDRENS HOSPITAL OF PHILADELP | EXPANDED ACCESS PROGRAM FORSNDX-5613IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LEUKEMIAS WITH GENETIC ALTERATIONS ASSOCIATED WITH HOXA OVEREXPRESSION | No dispute reported | 06/30/2026 | 1249049736 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,075.00 | 09/22/2025 | Covered Recipient Teaching Hospital The Childrens Hospital Of Philadelp | An Open-label, First-in-human, Dose-escalation Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR-MDS) | No dispute reported | 06/30/2026 | 1226129736 |
| Principal investigator 1 | Astellas Pharma Global Development | $7,615.00 | 09/18/2025 | Covered Recipient Teaching Hospital The Childrens Hospital Of Philadelp | A Phase 1/2, Multicenter, Open-Label, Single Arm, Dose Escalation and Expansion Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1234181060 |
| Principal investigator 1 | Astellas Pharma Global Development | $5,862.50 | 09/18/2025 | Covered Recipient Teaching Hospital The Childrens Hospital Of Philadelp | A Phase 1/2, Multicenter, Open-Label, Single Arm, Dose Escalation and Expansion Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1234181062 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,675.00 | 08/11/2025 | Covered Recipient Teaching Hospital The Childrens Hospital Of Philadelp | An Open-label, First-in-human, Dose-escalation Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR-MDS) | No dispute reported | 06/30/2026 | 1226129714 |
| Principal investigator 1 | ABBVIE INC. | $310.28 | 07/14/2025 | Non-covered Recipient Entity ACM MEDICAL LABORATORY INC | B19-061 Ph 3 Pediatric Study of venetoclax and chemotherapy | No dispute reported | 06/30/2026 | 1202498126 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,675.00 | 06/23/2025 | Covered Recipient Teaching Hospital The Childrens Hospital Of Philadelp | An Open-label, First-in-human, Dose-escalation Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR-MDS) | No dispute reported | 06/30/2026 | 1226129706 |
| Principal investigator 1 | ABBVIE INC. | $1,687.50 | 06/17/2025 | Covered Recipient Teaching Hospital THE CHILDRENS HOSPITAL OF PHILADELP | B19-061 Ph 3 Pediatric Study of venetoclax and chemotherapy | No dispute reported | 06/30/2026 | 1202422775 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $17,110.80 | 05/27/2025 | Covered Recipient Teaching Hospital The Childrens Hospital Of Philadelp | An Open-label, First-in-human, Dose-escalation Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR-MDS) | No dispute reported | 06/30/2026 | 1226129698 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,540.00 | 05/08/2025 | Covered Recipient Teaching Hospital The Childrens Hospital Of Philadelp | A Phase 1/2, Multicenter, Open-Label, Single Arm, Dose Escalation and Expansion Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1234181058 |
| Principal investigator 1 | Syndax Pharmaceuticals, Inc. | $15,354.50 | 05/05/2025 | Covered Recipient Teaching Hospital THE CHILDRENS HOSPITAL OF PHILADELP | EXPANDED ACCESS PROGRAM FORSNDX-5613IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LEUKEMIAS WITH GENETIC ALTERATIONS ASSOCIATED WITH HOXA OVEREXPRESSION | No dispute reported | 06/30/2026 | 1249049734 |
| Principal investigator 1 | Incyte Corporation | $14,313.00 | 04/16/2025 | Covered Recipient Teaching Hospital The Childrens Hospital Of Philadelp | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearranged and or JAK Pathway Mutant Acute Lymphoblastic Leukemia | No dispute reported | 06/30/2026 | 1240489255 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,400.00 | 04/14/2025 | Covered Recipient Teaching Hospital The Childrens Hospital Of Philadelp | An Open-label, First-in-human, Dose-escalation Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR-MDS) | No dispute reported | 06/30/2026 | 1226129689 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $61,033.10 | 04/07/2025 | Covered Recipient Teaching Hospital The Childrens Hospital Of Philadelp | An Open-label, First-in-human, Dose-escalation Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR-MDS) | No dispute reported | 06/30/2026 | 1226129685 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,189.20 | 03/24/2025 | Covered Recipient Teaching Hospital The Childrens Hospital Of Philadelp | An Open-label, First-in-human, Dose-escalation Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR-MDS) | No dispute reported | 06/30/2026 | 1226129682 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $5,943.75 | 03/06/2025 | Non-covered Recipient Entity CHILDRENS HOSPITAL OF PHILADELPHIA | A Multi-center, Open-label Study to Determine the Dose and Safety of Oral Asciminib in Pediatric Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP), Previously Treated With One or More Tyrosine Kinase Inh | No dispute reported | 06/30/2026 | 1190298924 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $810.00 | 02/24/2025 | Covered Recipient Teaching Hospital The Childrens Hospital Of Philadelp | An Open-label, First-in-human, Dose-escalation Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR-MDS) | No dispute reported | 06/30/2026 | 1226129669 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $55,702.80 | 02/24/2025 | Covered Recipient Teaching Hospital The Childrens Hospital Of Philadelp | An Open-label, First-in-human, Dose-escalation Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR-MDS) | No dispute reported | 06/30/2026 | 1226129674 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $62,464.50 | 02/24/2025 | Covered Recipient Teaching Hospital The Childrens Hospital Of Philadelp | An Open-label, First-in-human, Dose-escalation Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR-MDS) | No dispute reported | 06/30/2026 | 1226129678 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $71,816.40 | 02/10/2025 | Covered Recipient Teaching Hospital The Childrens Hospital Of Philadelp | An Open-label, First-in-human, Dose-escalation Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR-MDS) | No dispute reported | 06/30/2026 | 1226129665 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,591.75 | 02/04/2025 | Covered Recipient Teaching Hospital The Childrens Hospital Of Philadelp | An Open-label, First-in-human, Dose-escalation Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR-MDS) | No dispute reported | 06/30/2026 | 1226129662 |
| Principal investigator 1 | Syndax Pharmaceuticals, Inc. | $3,875.00 | 01/29/2025 | Covered Recipient Teaching Hospital THE CHILDRENS HOSPITAL OF PHILADELP | AUGMENT-102: A PHASE 1, OPEN-LABEL, DOSE-ESCALATION STUDY TO EVALUATE SAFETY, TOLERABILITY AND PRELIMINARY ANTI-LEUKEMIC ACTIVITY OF SNDX-5613 IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY LEUKEMIAS HARBORING ALTERATIONS IN KMT2A/MLL, NUCLEOPHOSMIN 1 (NPM1), AND NUCLEOPORIN 98 (NUP98) GENES | No dispute reported | 06/30/2026 | 1249049732 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $2,965.14 | 01/01/2025 | Covered Recipient Teaching Hospital The Childrens Hospital Of Philadelp | A Multi-center, Open-label Study to Determine the Dose and Safety of Oral Asciminib in Pediatric Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP), Previously Treated With One or More Tyrosine Kinase Inh | No dispute reported | 06/30/2026 | 1190294748 |